Cotellic (Cobimetinib)

Brand Options

arrow pointer

Brand Name : Cotellic

Marketing Authorization Holder : Genentech

Prescription Required

 
 
No Generic Medicine available for this medicine.

Product Details

Cotellic

Save 40% with brand Cotellic from Europe.

Non-english packaging - English label and English insert included. Plan in advance - allow us 7 days to ship your medicine

Manufacturer for all European Cotellic: Roche Pharma AG Emil-Barell-Strasse 1 79639 Grenzach-Wyhlen Germany

Information about Cotellic (Cobimetinib)

Cotellic is a prescription medication used in the treatment of certain types of cancer. Its active ingredient, cobimetinib, is a targeted therapy that inhibits specific proteins involved in cancer cell growth and proliferation. Cotellic is often used in combination with other cancer treatments to improve efficacy and outcomes.

Product Highlights

  • Cotellic specifically targets and inhibits MEK1 and MEK2 proteins, which are part of the MAPK/ERK pathway involved in tumor growth.
  • Typically used in combination with vemurafenib for the treatment of melanoma with specific genetic mutations, enhancing overall treatment effectiveness.
  • Primarily used to treat unresectable or metastatic melanoma with a BRAF V600E or V600K mutation when used in combination with vemurafenib.
  • May be explored for use in other cancers with similar genetic mutations, depending on ongoing clinical research and trials.

Key Ingredient

  • Cobimetinib

Key Benefits

  • Specifically targets cancer cells with mutations in the MAPK/ERK pathway, potentially leading to better treatment outcomes.
  • When used with vemurafenib, it can provide a more comprehensive approach to treating melanoma with specific genetic profiles.

Direction of Use

  • Typically administered as an oral tablet, taken once daily for 21 days followed by a 7-day break, as part of a cycle. The specific dosage and schedule should be tailored to individual patient needs based on medical advice.
  • Take the tablets with or without food, and follow the prescribed dosing schedule carefully.

Recommended Dose Reductions for COTELLIC:

First Dose Reduction40 mg orally once daily
Second Dose Reduction20 mg orally once daily
Subsequent ModificationPermanently discontinue COTELLIC if unable to tolerate 20 mg orally once daily

Safety Concerns

  • May include diarrhea, nausea, vomiting, rash, and elevated liver enzymes.
  • Can include severe skin reactions, liver toxicity, heart problems, and eye issues. Regular monitoring by a healthcare provider is essential.
  • Cotellic may interact with other medications, so inform your healthcare provider of all drugs and supplements you are taking.

Avoid Cotellic (Cobimetinib) If

  • You have a known hypersensitivity or allergy to cobimetinib or any other component of the medication.
  • Not recommended for use during pregnancy or breastfeeding due to potential risks to the developing fetus or nursing infant.
  • Use with caution or avoid if you have severe liver impairment, as cobimetinib can affect liver function.
  • Caution is needed if you have a history of certain heart conditions, eye disorders, or severe skin reactions.


Image Image Image Image